Dupont, Jeanette <br/><br/>
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.  [electronic resource] 

 -  Acta oncologica (Stockholm, Sweden)  2007 
 - 330-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>0284-186X 
<br/><br/><label>Standard No.: </label>10.1080/02841860600949578  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Capecitabine<br/>Denmark<br/>Deoxycytidine--administration & dosage<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Epirubicin--administration & dosage<br/>Esophagogastric Junction--pathology<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Severity of Illness Index<br/>Stomach Neoplasms--drug therapy<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome